Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Name: Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Published: 2009
License: Public Domain

Cardiff University · 2009

ClinicalTrials.gov · Datasets · License: Public Domain · 2009

Open Source ↗

bladder cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer, recurrent urethral cancer, recurrent transitional cell cancer of the renal pelvis and ureter, metastatic transitional cell cancer of the renal pelvis and ureter, regional transitional cell cancer of the renal pelvis and ureter, posterior urethral cancer, urethral cancer associated with invasive bladder cancer, transitional cell carcinoma of the bladder, stage iv bladder cancer, recurrent bladder cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 1032085
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.